Cytovance Biologics
Oklahoma City, OK
Program data pending ClinicalTrials.gov matching
· Last scored 2026-04-29
61.5
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (8)
○ EMA GMP
○ MHRA GMP
Quick Facts: Cytovance Biologics
- Signal Score
- 61.5/100 (as of 2026-04-29)
- Quality Compliance
- Assessment pending
- Headquarters
- Oklahoma City, OK
- Founded
- 2006
- Max Bioreactor Scale
- 2,000L
- Website
- https://cytovance.com/
- Modalities
- Microbial Fermentation, Biologics, Recombinant Proteins, Mammalian Cell Culture, Plasmid DNA
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesMicrobial Fermentation, Biologics, Recombinant Proteins, Mammalian Cell Culture, Plasmid DNA
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
63.0
Broad modality coverage (5 modalities)
Sites: Oklahoma City, OK
Source: SEC EDGAR, press monitoring, company profiles
1 manufacturing site
StatusAvailable
Broad modality coverage (5 modalities)
Sites: Oklahoma City, OK
Recent Press8 articles
Broad modality coverage (5 modalities)
Recent News 8 articles
Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing - BioSpace
Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing BioSpace
Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing - Sahm
Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing Sahm
Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 with Selection of Cytovance Biologics for cGMP Manufacturing - irw-press.com
Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 with Selection of Cytovance Biologics for cGMP Manufacturing irw-press.com
Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing - StreetInsider
Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing StreetInsider
Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing - Yahoo Finance Singapore
Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing Yahoo Finance Singapore
Anixa Biosciences Advances Breast Cancer Vaccine to Phase 2 Trials with Cytovance Biologics as cGMP Manufacturer - geneonline.com
Anixa Biosciences Advances Breast Cancer Vaccine to Phase 2 Trials with Cytovance Biologics as cGMP Manufacturer geneonline.com
Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing - PR Newswire
Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing PR Newswire
Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing - Morningstar
Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing Morningstar
Frequently Asked Questions About Cytovance Biologics
What is Cytovance Biologics's CDMO Signal Score?
Cytovance Biologics has a Signal Score of 62/100, based on quality, operations, financial stability, and capacity data.
Evaluating Cytovance Biologics for a manufacturing program?
Use the free AI matchmaker to compare Cytovance Biologics against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Richter BioLogics
Hamburg, Germany
Signal Score: 82.9
Plasmid DNA, Recombinant Proteins, VHH/Nanobodies, Bacterial Vaccines, Biologics
53Biologics
Boecillo, Valladolid, Spain
Biologics, Recombinant Proteins, Plasmid DNA, mRNA, Enzymes, Vaccines, Antibody Fragments
3P Biopharmaceuticals (now 3PBIOVIAN)
Pamplona-Noáin, Spain
Biologics (microbial & mammalian), AAV, Adenoviral, Lentiviral, Cell Therapy, Plasmid DNA, Recombinant Proteins, Biosimilars, Fill/Finish (recombinant proteins & viral vectors)
BioCina
Adelaide, Australia
Biologics (Microbial), Plasmid DNA, mRNA, LNP, Sterile Fill-Finish, Recombinant Proteins, Vaccines, Biosimilars, High Potency/Oncology Injectables, Blow-Fill-Seal
Altruist Biologics
Suzhou, China
Biologics, mAb, Bispecific/Multispecific Antibodies, Fusion Proteins, Recombinant Proteins, ADC, Cell Therapy, Gene Therapy